| 1. |
Fang ZW, Chen J, Teng S, et al. Analysis of soft tissue sarcomas in 1118 cases. Chin Med J, 2009, 122(1): 51-53.
|
| 2. |
Dickson MA, Tap WD, Keohan ML, et al. PhaseⅡtrial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. J Clin Oncol. 2013, 31(16): 2024-2028.
|
| 3. |
Fletcher CDM, Bridge JA, Hogendoorn P, et al. WHO classification of tumours of soft tissue and bone. 4th ed. Lyon: IARC Press, 2013.
|
| 4. |
Goldblum JR. An approach to pleomorphic sarcomas: can we subclassify, and does it matter?. Mod Pathol, 2014, 27(Suppl 1): S39-S46.
|
| 5. |
Nishida Y, Tsukushi S, Nakashima H, et al. Clinicopathologic prognostic factors of pure myxoid liposarcoma of the extremities and trunk wall. Clin Orthop Relat Res, 2010, 468(11): 3041-3046.
|
| 6. |
Pattani KM, Lian TS. A unique case of infraorbital myxoid liposarcoma. Ear Nose Throat J, 2010, 89(9): 466-7.
|
| 7. |
Ono S, Rana M, Takechi M, et al. Myxolipoma in the tongue: a clinical case report and review of the literature. Head Neck Oncol, 2011, 3: 50.
|
| 8. |
Hasanabadi1 M. Huge myxoid liposarcoma of the esophagus: a case report. Acta Med Iran, 2011, 49(2): 118-121.
|
| 9. |
Saito T, Ryu M, Fukumura Y, et al. A case of myxoid liposarcoma of the breast. Int J Clin Exp Pathol, 2013, 6(7): 1432-1436.
|
| 10. |
Granados-Lopez SL, Tavares-Garcia JS, Perez-Contreras A. Myxoid liposarcoma of the lumbosacral spine. Clinical case report. Rev Med Inst Mex Seguro Soc, 2013, 51(5): 588-591.
|
| 11. |
Tirabosco R, Arora R, Ye H, et al. Primary myxoid liposarcoma of the ovary in an adolescent girl: a case report. Int J Gynecol Pathol, 2010, 29(3): 256-259.
|
| 12. |
Buehler D, Marburger TB, Billings SD. Primary subcutaneous myxoid liposarcoma: a clinicopathologic review of three cases with molecular confirmation and discussion of the differential diagnosis. J Cutan Pathol, 2014, 41(12): 907-915.
|
| 13. |
Pollack SM, Jungbluth AA, Hoch BL, et al. NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma. Cancer, 2012, 118(18): 4564-4570.
|
| 14. |
Kubo T, Sugita T, Shimose S, et al. Conservative surgery for well-differentiated liposarcomas of the extremities adjacent to major neurovascular structures. Surg Oncol, 2006, 15(3): 167-171.
|
| 15. |
Dossi R, Frapolli R, Di Giandomenico S, et al. Antiangiogenic activity of trabectedin in myxoid liposarcoma: involvement of host TIMP-1 and TIMP-2 and tumor thrombospondin-1. Int J Cancer, 2015, 136(3): 721-729.
|
| 16. |
Di Giandomenico S, Frapolli R, Bello E, et al. Mode of action of trabectedin in myxoid liposarcomas. Oncogene, 2014, 33(44): 5201-5210.
|
| 17. |
Steinmann S, Gali-Muhtasib H, Huebner K, et al. Hsp90 inhibition by AUY922 as an effective treatment strategy against myxoid liposarcoma. Cancer Lett, 2015, 367(2): 147-156.
|
| 18. |
Dogan U, Zamani A, Gormus N, et al. The first case report of a metastatic myxoid liposarcoma invading the left atrial cavity and pulmonary vein. Heart Surg Forum, 2011, 14(4): E261-E263.
|
| 19. |
Tabata I, Nishida Y, Sugiura H, et al. A study of inter-alpha-trypsin inhibitor chains expression in liposarcomas. Eur J Surg Oncol, 2003, 29(8): 665-669.
|
1/5
WeChat